Tilray Brands, Inc.
TLRY Healthcare Drug Manufacturers Specialty & Generic
Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TLRY
Tilray Brands, Inc. (TLRY) P/E ratio
Tilray Brands, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 45.1× (March 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Aug 2026 | 0.0× | — |
| May 2026 | 0.0× | — |
| Feb 2026 | 0.0× | — |
| Nov 2025 | 0.0× | — |
| 40 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| EVO Evotec AG compare | n/m |
| TLRY Tilray Brands, Inc. | n/m |
| EOLS Evolus, Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 4.4× |
| KMDA Kamada Ltd. compare | 20.4× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)